we conduct our business through three reportable segments: u.s. pharmaceutical and specialty solutions, european pharmaceutical solutions and medical-surgical solutions. all remaining operating segments and business activities that are not significant enough to require separate reportable segment disclosure are included in other, which primarily consists of mckesson canada, mckesson prescription technology solutions ("mrxts") and our investment in change healthcare llc ("change healthcare jv"), which was split-off from the company in the fourth quarter of 2020 as further discussed in this financial review. our organizational structure also includes corporate, which consists of income and expenses associated with administrative functions and projects, and the results of certain investments. the factors for determining the reportable segments include the manner in which management evaluates the performance of the company combined with the nature of the individual business activities. we evaluate the performance of our operating segments on a number of measures, including revenues and operating profit before interest expense and income taxes. refer to financial note 24, "segments of business," to the accompanying consolidated financial statements included in this annual report on form 10-k for a description of these segments.